The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX(®) Testing

SIMPLE SUMMARY: As we move forward into the era of precision cancer medicine, we must consider the current state of the health care economy, as well patient access to quality health care. While multigene assays such as Oncotype DX(®) have certainly allowed for a more individualized approach to the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Bradley M., Finkelman, Brian S., Hicks, David G., Numbereye, Numbere, Moisini, Ioana, Dhakal, Ajay, Skinner, Kristin, Sanders, Mary Ann G., Wang, Xi, Shayne, Michelle, Schiffhauer, Linda, Katerji, Hani, Zhang, Huina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913115/
https://www.ncbi.nlm.nih.gov/pubmed/36765860
http://dx.doi.org/10.3390/cancers15030903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913115/
https://www.ncbi.nlm.nih.gov/pubmed/36765860
http://dx.doi.org/10.3390/cancers15030903

Ejemplares similares